BioSpace News Archive

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Chief Executive Officer (CEO), John Sperzel, has promoted Tony Pare to the newly created position of Chief Commercial Officer (CCO), effective immediately. Mr. Pare previously served as Vice President and General Manager – International at T2 Biosystems.

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2020, at 9:00 a.m. PT.

Cytokinetics, Inc. (Nasdaq: CYTK) today announced its Vision 2025 and provided guidance for corporate milestones expected to occur in 2020.

New assets span multiple modalities and target an endocrine disorder, inherited eye disease, genetically driven deafness and autism spectrum disorder

Revolution Medicines, Inc., today announced that preliminary data from the company’s Phase 1 clinical trial (RMC-4630-01) of RMC-4630 were reported in podium and poster presentations at the 6th AACR-IASLC International Joint Conference: Lung Cancer Translational Science

- TAVALISSE® preliminary 4Q net product sales of approximately $13.8 mln, YoY increase of 90%; preliminary 4Q total revenues of approximately $15.4 mln - Received European approval of fostamatinib disodium hexahydrate for adult patients with chronic ITP - Phase 3 pivotal trial for warm AIHA on track with 20 patients enrolled, including 15 in last 2 months [13-January-2020]

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach, will be presenting at the 38th Annual J.P. Morgan Healthcare Conference at 12:00 p.m. PST on Wednesday, January 15, 2020.

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) today announced 2020 milestones for IPI-549, a first-in-class, oral, immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition and provided financial guidance for 2020.

Waters Corporation announced that it has entered into a definitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including software and robotics.

DexCom, Inc., the leader in continuous glucose monitoring, today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be approximately $457 million, an increase of 35% over the fourth quarter of 2018.